APRIL 2003
C O N T E N T S
SPECIAL ISSUE: reports from the 10th Conference on Retroviruses and Opportunistic Infections, Boston
CONFERENCE REPORTS
10th Conference on Retroviruses and Opportunistic Infections (CROI)
CROI: ANTIRETROVIRALS
- Pipeline compounds in Phase 2/3 studies
- 96-week results show tenofovir-including regimen has side-effect advantages over d4T regimen in treatment naïve patients
- 2NN results – nevirapine and efavirenz in prospective randomised head-to-head study
- NIH/NIAID study of generic drugs shows results consistent with stringent manufacturing standards
CROI: TREATMENT STRATEGIES
CROI: WOMENS STUDIES
CROI: SIDE EFFECTS
- Tenofovir and renal tubular dysfunction
- Approaches to treatment of lipodystrophy
- Surgery for buffalo hump shows variable results depending on method
- Other studies – nucleosides and switching to abacavir; importance of lipoatrophy and buffalo hump
- HAART to HEART: cardiovascular risk in HIV
- Alendronate, vitamin D and calcium are safe and effective treatment for HIV-associated bone loss
- Bone loss and fat loss are closely related in HIV patients on HAART
CROI: HEPATITIS COINFECTION
- Low dose 200/100 IDV/RTV managed by TDM in substudy of co-infected patients
- 12-week response predicts which HIV-HCV coinfected patients will not benefit from continued pegylated interferon plus ribavirin
- Pegylated interferon associated with eye disorders
CROI: RESISTANCE
TREATMENT ACCESS
- Global Fund gives $210 million for treatment in Thailand
- Anti-HIV combination drug for Indonesia
- Indian generic drug maker Ranbaxy Laboratories to launch own-brand abacavir
- Bush blocks deal allowing cheap drugs
- Roche to sell nelfinavir, saquinavir at cost to least-developed nations
- South Africa appoints another dissident
IMMUNOLOGY
OTHER NEWS
- UK HIV new cases at record high
- Trizivir-only arm closed in PI-sparing, naïve therapy trial
- Reduced testosterone levels in HIV-positive women
- Fosamprenavir expanded access available in UK
- European approval of adefovir for hepatitis B
- European activists highlight importance of gender based research: women with HIV suffer differently
- Roche prices enfuvirtide (T-20) at €18,980 a year – making it the most expensive HIV drug yet
- European positive opinion for tenofovir for first line therapy
- Vaxgen announces disappointing results from first large international vaccine trial
- GMHC criticises Vaxgen for obfuscation of trial results
- Antibiotic-resistant skin infections spreading among gay men, also in prisons
ON THE WEB
- Further Glasgow and Retrovirus reports
- Medscape: articles in full from AIDS, Journal AIDS etc
- Contents of newsletters now online: Beta, amfAR Insider, PRN Notebook, GMHC Treatment Issues
- New HIVinSite Knowledge Base chapters: Molecular insights into HIV biology; Surgery in patients with HIV; HIV transmission and prevention in prisons; Epidemiology of HIV/AIDS in the United States; Coinfection with Hepatitis viruses and HIV
- HHS clinical guide on palliative care of HIV/AIDS patients
PUBLICATIONS AND SERVICES FROM i-BASE
h-tb
HIV Treatment Bulletin
HTB is a monthly journal published in print and electronic format by HIV i-Base. As with all i-Base publications, subscriptions are free and can be ordered:
directly
from the i-Base website:
http://www.i-base.info/forms/index.html
by sending an email to:
subscriptions@i-Base.org.uk
by fax
+44 (0) 20 7407 8488
or post:
i-Base
3rd Floor East
Thrale House
44-46 Southwark Street
Bankside
London
SE1 1UN
Editor in Chief: Paul Blanchard
Editor: Simon Collins
Associate Editor: Graham McKerrow
Commissioning Editor: Polly Clayden
Medical Consultants:
Dr Sanjay Bhagani,
Royal Free Hospital, London
Dr Karen Beckerman,
Bellevue Hospital, New York.
Prof. Clive Loveday,
International Laboratory Virology Centre.
Dr Graeme Moyle,
Chelsea & Westminster Hospital, London.
Dr Stefan Mauss,
Düsseldorf.
Dr Gareth Tudor-Williams, Imperial College, London.
HTB is a not-for-profit community publication that aims to provide an review of the most important medical advances related to clinical management of HIV and its related conditions as well as access to treatments.
Some articles are reproduced from other respected sources and copyright for these articles remains with the original authors and sources, as indicated at the end of each article.
We thank those organisations for recognising the importance of providing widely distributed free access to information both to people living with HIV and to healthcare professionals involved in their care. We also thank them for permission to distribute their excellent work and we encourage HTB readers to visit the source websites for further access to their coverage of HIV treatment.
Articles written and credited to i-Base writers, as with all i-Base originated material, remains the copyright of HIV i-Base, but these articles may be reproduced by community and not-for-profit organisations without individual written permission and reproduction is encouraged. A credit and link to the original author, the HTB issue and the i-Base website is always appreciated.
HIV i-Base is a registered charity no 1081905 and co reg no 3962064
